Insulet Corporation (PODD)
Free
No email, no account, no signup.
Pulling latest news for Insulet Corporation…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Technology
Sector
Medical technology, diabetes care
Market Cap
$12.1B
Market sentiment
Sentiment has weakened materially following the correction/recall (patient-safety, brand, and cost concerns), partially offset by positive product upgrades and strong underlying growth.
Why NEUTRAL ?
The voluntary correction is a material risk event (potential costs, regulatory follow-up, and trust impact) warranting a position review until there is clearer visibility on scope, remediation pace, and demand/margin impact. The EOFlow appellate outcome reduces legal downside but does not offset the near-term increase in product/execution risk.
- Review: pause/additional diligence on exposure; avoid adding until the company quantifies the net impact of the correction and demonstrates stable quality and fulfillment through the next quarter.
We're already tracking Insulet Corporation — here are the latest events we've registered
Recent News
- Since the Q1 print (May 6, 2026), Insulet initiated a voluntary medical device correction for certain Omnipod 5/DASH/Eros pods due to a manufacturing issue that may cause insulin under-delivery (about 7 million pods affected; 24 serious events reported). On May 28, an appeals court overturned a $59M judgment against EOFlow in a trade-secrets case. In early June, Insulet also communicated a rollout of an improved Omnipod 5 algorithm and expanded compatibility with Abbott FreeStyle Libre 3 Plus.
Want to know how this news affects Insulet Corporation? Order the analysis.
Order analysis – Catalysts
6 Aug 2026 — Q2 2026 earnings (first after the recall)
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Insulet Corporation will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.